Ophiomics

Executive Summary

Ophiomics is a clinical-stage, ISO 13485-certified medtech company headquartered in Porto, Portugal, dedicated to precision liver medicine. The company develops AI-driven diagnostic tools that integrate genomics to support the diagnosis, prognosis, treatment selection, and clinical follow-up of liver diseases. Founded in 2019, Ophiomics aims to transform liver care by providing non-invasive, data-driven solutions that improve patient outcomes and reduce healthcare costs. With a focus on early detection and personalized treatment, the company addresses the growing global burden of liver diseases, including non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, and hepatocellular carcinoma. Ophiomics' technology combines machine learning algorithms with genomic biomarkers, enabling accurate risk stratification and therapeutic monitoring. The company is currently in the clinical validation phase, positioning itself for commercialization and potential partnerships with pharmaceutical firms and healthcare providers. Its ISO 13485 certification underscores its commitment to quality management in medical device development.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Pivotal Clinical Trial for Liver Diagnostic Product70% success
• Q3 2026Presentation of Validation Data at Major Hepatology Conference (e.g., AASLD or EASL)80% success
• H1 2027Partnership with Pharmaceutical Company for Companion Diagnostics in Liver Disease60% success